FDA Class II Recall: Cardinal Health's Fluticasone Propionate Nasal Spray Due to Temperature Excursions
Cardinal Health initiated a Class II recall for Fluticasone Propionate Nasal Spray (ANDA077538) due to CGMP deviations involving temperature excursions. This voluntary action, impacting 6 units manufactured for Apotex Corp., highlights critical vulnerabilities in pharmaceutical storage and distribution networks. Decision-makers must reassess temperature control protocols to mitigate similar supply chain risks.
FDA Class II Recall: Fluticasone Propionate Nasal Spray Impacted by Temperature Excursions
On January 26, 2022, CARDINAL HEALTHCARE initiated a voluntary Class II recall, designated D-0182-2024, for specific batches of Fluticasone Propionate Nasal Spray USP, 50MCG per spray. This critical action, reported to the FDA on January 3, 2024, stemmed from Current Good Manufacturing Practice (CGMP) deviations, specifically the exposure of products to temperatures outside their labeled storage conditions. The affected product, identified by NDC 60505-0829-1 and associated with ANDA077538, is a human prescription drug intended for intranasal use, manufactured for Apotex Corp. The recall involved a limited quantity of 6 units from batches TE9159 and TE8156. For procurement directors and regulatory affairs heads, this event underscores the non-negotiable importance of maintaining strict environmental controls throughout the pharmaceutical supply chain. Even a Class II classification, indicating a situation where exposure may cause temporary or medically reversible adverse health consequences, highlights the potential for patient risk and regulatory scrutiny if storage integrity is compromised. The termination of this recall on September 29, 2024, signifies that Cardinal Healthcare has completed its corrective actions for the identified units, but the underlying systemic vulnerabilities remain a focus for industry vigilance.
Operational and Supply Chain Implications for Pharmaceutical Distributors
This recall event, initiated by CARDINAL HEALTHCARE, a major distributor based in Dublin, OH, United States (postal code 43017-1094), brings into focus the critical role of distributors in maintaining product quality post-manufacturing. While the Fluticasone Propionate Nasal Spray was manufactured for Apotex Corp., the responsibility for proper storage and handling within the distribution network falls squarely on firms like Cardinal Healthcare. The nationwide USA distribution pattern for the recalled batches, despite the small quantity of 6 units, indicates that temperature control failures can occur at various points. For supply chain VPs, this incident serves as a stark reminder that robust quality agreements with third-party logistics providers and internal distribution centers are paramount. Ensuring that all parties adhere to the labeled storage conditions for every product, particularly sensitive pharmaceuticals like nasal sprays, is essential to prevent product degradation and maintain efficacy. Business development executives must consider how such incidents, even minor in scale, can impact brand reputation and customer trust if not managed with stringent quality assurance protocols. Proactive monitoring and validation of storage environments are critical to prevent similar CGMP deviations from escalating into broader supply chain disruptions.
Regulatory Compliance and Quality System Vigilance for Drug Products
The FDA's classification of this event as a Class II recall for CGMP deviations related to temperature control emphasizes the agency's zero-tolerance stance on breaches of product integrity. For regulatory affairs heads, this highlights the necessity of comprehensive quality management systems that extend beyond manufacturing to encompass all aspects of storage and distribution. The fact that the recall was 'Firm initiated' by Cardinal Healthcare indicates a level of internal vigilance, but the underlying issue of temperature excursions points to a potential gap in proactive monitoring or corrective actions. While the recall is now terminated as of September 29, 2024, the incident serves as a benchmark for evaluating internal and external quality audits. Companies must ensure their quality systems are not only documented but effectively implemented and routinely verified to prevent deviations that could compromise drug stability, potency, and patient safety. This applies to all human prescription drugs, including generic formulations like Apotex Corp.'s Fluticasone Propionate. Continuous training for personnel involved in handling and storage, coupled with advanced environmental monitoring technologies, are crucial investments to safeguard product quality and maintain regulatory compliance across the entire pharmaceutical lifecycle.